Drug Trial Radar · NCT07850752
A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
340
Planned (sponsor's estimate)
Start
Nov 11, 2026
Primary completion
Sep 17, 2028
Study completion Dec 25, 2030
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase IIIb, multicenter, two-arm, randomized, double-blind, parallel group study to evaluate the efficacy and safety of zigakibart + atrasentan compared to zigakibart + placebo in patients with primary IgAN at risk of disease progression.
Conditions
- IgA Nephropathy (IgAN)
Interventions
zigakibartBiological
Solution for injection via PFS-NSD
atrasentanDrug
Tablet
PlaceboDrug
Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in proteinuria from Baseline to Week 36, based on 24 hour urine collectionTime frame: Baseline, Week 36
Locations
11 sites in 3 countries. Site status is shown where the registry gives one.
Nephrology Consultants LLC
Huntsville, Alabama · Recruiting
West Coast Kidney Institute
Fremont, California · Recruiting
Nephrology Associates PA
Newark, Delaware · Recruiting
Florida Kidney Physicians
Riverview, Florida · Recruiting
Florida Kidney Physicians LLC
Temple Terrace, Florida · Recruiting
Southeast Kidney Associates
East Point, Georgia · Recruiting
DaVita Clinical Research
Las Vegas, Nevada · Recruiting
Northern Assoc of Northern VA
Fairfax, Virginia · Recruiting
Novartis Investigative Site
Nedlands, Western Australia, Australia · Recruiting
Novartis Investigative Site
Beersheba, Israel · Recruiting
Novartis Investigative Site
Petah Tikva, Israel · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.